We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
Read MoreHide Full Article
Jazz Pharmaceuticals (JAZZ - Free Report) announced that it has entered into a licensing agreement with Werewolf Therapeutics (HOWL - Free Report) to gain rights to the latter’s pre-clinical oncology candidate WTX-613.
Werewolf's pipeline candidate WTX-613 is an engineered cytokine pro-drug that gets activated specifically within the tumor microenvironment and stimulates particular receptors, such as interferon alpha 2b on cancer-fighting immune effector cells.
Per Jazz management, WTX-613 has the potential to treat a wide range of cancer types in different stages and also in combination with other cancer therapies, including immune checkpoint inhibitors, targeted therapies and chemotherapy.
Werewolf's WTX-613 demonstrated anti-tumor activity in preclinical models. Jazz expects to submit an investigational new drug (IND) application to the FDA in 2023 to support initiation of a clinical study on the candidate.
Per the terms of the agreement, Jazz will pay $15 million of upfront payment to Werewolf. JAZZ will also pay up to $1.26 billion as development, regulatory and sales milestone fees as well as royalties on the potential sales to Werewolf.
Shares of Jazz have risen 32.4% against the industry’s decrease of 13.5%.
Image Source: Zacks Investment Research
Jazz derives majority of its revenues from its sleep disorder portfolio, which is included in its Neuroscience portfolio. JAZZ diversified its Neuroscience portfolio in 2021 with the acquisition of the British cannabinoid drug company GW Pharmaceuticals. The buyout added epilepsy and multiple sclerosis drugs to its portfolio.
Jazz has been diversifying into the oncology segment for the past few years through inorganic as well as organic growth. JAZZ’s oncology portfolio has marketed drugs. It has constantly focused on expanding the label of its marketed drugs that boosted its oncology revenues and the trend will likely continue.
The licensing agreement with Werewolf will add a promising candidate to its pipeline, which Jazz believes, provides it with an opportunity to expand into immuno-oncology. Management also states that the agreement will support JAZZ’s plan to deliver at least five additional novel therapies to patients by the end of the decade.
The Collegium stock has risen 9.2% so far this year. The Zacks Consensus Estimate for COLL’s 2022 earnings has gone up from $3.79 to $5.59 over the past 60 days.
Collegium beat earnings estimates in one of the trailing four quarters and missing the mark on three occasions. COLL delivered a negative earnings surprise of 57.55%, on average.
Estimates for Assertio Holdings’ 2022 earnings have improved from 20 cents per share to 35 cents per share over the past 60 days. The stock has gained 22.1% so far this year.
Assertio Holdings beat earnings estimates in two of the trailing four quarters and missed the mark twice. ASRT delivered an earnings surprise of 20.83%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
Jazz Pharmaceuticals (JAZZ - Free Report) announced that it has entered into a licensing agreement with Werewolf Therapeutics (HOWL - Free Report) to gain rights to the latter’s pre-clinical oncology candidate WTX-613.
Werewolf's pipeline candidate WTX-613 is an engineered cytokine pro-drug that gets activated specifically within the tumor microenvironment and stimulates particular receptors, such as interferon alpha 2b on cancer-fighting immune effector cells.
Per Jazz management, WTX-613 has the potential to treat a wide range of cancer types in different stages and also in combination with other cancer therapies, including immune checkpoint inhibitors, targeted therapies and chemotherapy.
Werewolf's WTX-613 demonstrated anti-tumor activity in preclinical models. Jazz expects to submit an investigational new drug (IND) application to the FDA in 2023 to support initiation of a clinical study on the candidate.
Per the terms of the agreement, Jazz will pay $15 million of upfront payment to Werewolf. JAZZ will also pay up to $1.26 billion as development, regulatory and sales milestone fees as well as royalties on the potential sales to Werewolf.
Shares of Jazz have risen 32.4% against the industry’s decrease of 13.5%.
Image Source: Zacks Investment Research
Jazz derives majority of its revenues from its sleep disorder portfolio, which is included in its Neuroscience portfolio. JAZZ diversified its Neuroscience portfolio in 2021 with the acquisition of the British cannabinoid drug company GW Pharmaceuticals. The buyout added epilepsy and multiple sclerosis drugs to its portfolio.
Jazz has been diversifying into the oncology segment for the past few years through inorganic as well as organic growth. JAZZ’s oncology portfolio has marketed drugs. It has constantly focused on expanding the label of its marketed drugs that boosted its oncology revenues and the trend will likely continue.
The licensing agreement with Werewolf will add a promising candidate to its pipeline, which Jazz believes, provides it with an opportunity to expand into immuno-oncology. Management also states that the agreement will support JAZZ’s plan to deliver at least five additional novel therapies to patients by the end of the decade.
Jazz Pharmaceuticals PLC Price
Jazz Pharmaceuticals PLC price | Jazz Pharmaceuticals PLC Quote
Zacks Rank & Stocks to Consider
Jazz currently carries a Zacks Rank #3 (Hold). Two better-ranked stocks from the same sector are Collegium Pharmaceutical (COLL - Free Report) and Assertio Holdings (ASRT - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Collegium stock has risen 9.2% so far this year. The Zacks Consensus Estimate for COLL’s 2022 earnings has gone up from $3.79 to $5.59 over the past 60 days.
Collegium beat earnings estimates in one of the trailing four quarters and missing the mark on three occasions. COLL delivered a negative earnings surprise of 57.55%, on average.
Estimates for Assertio Holdings’ 2022 earnings have improved from 20 cents per share to 35 cents per share over the past 60 days. The stock has gained 22.1% so far this year.
Assertio Holdings beat earnings estimates in two of the trailing four quarters and missed the mark twice. ASRT delivered an earnings surprise of 20.83%, on average.